Berapakah harga Abivax S.A. (ABVX)

Harga Abivax S.A. (ABVX) adalah $121.34

Apakah topi pasaran Abivax S.A. (ABVX)

Cap pasaran Abivax S.A. (ABVX) adalah $10.58B

Abivax S.A. (ABVX) Hasil Dividen

Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.

Tahun	Hasil Dividen	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Hasil Dividen

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Syarikat	Hasil Dividen	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH

Syarikat

Hasil Dividen

Negara

Vertex Pharmaceuticals Incorporated

VRTX.US

0.00%

Argenx SE

ARGX.US

0.00%

Moderna, Inc.

MRNA.US

0.00%

CSL Limited

CSL.AX

3.12%

Lonza Group AG

LONN.SW

0.00%

Abivax S.A.

ABVX

Kategori